Current News

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class. .

ILC Therapeutics’ proprietary technology platform has delivered a new therapeutic class of hybrid interferons, engineered to deliver reduced toxicity, enhanced safety and improved efficacy, with broad applications across multiple therapeutic areas. The Company is building a diverse pipeline of first-in-class/ best-in-class innovative hybrid interferons with differentiated modes of action that have blockbuster potential, initially focused on virology and dermatology. ILC Therapeutics is led by an experienced Board and management team with a proven track record of building successful drug development companies with commercially attractive assets.

Paul McManus, Founder and Managing Director of Walbrook PR, said: “We’re delighted to partner with ILC Therapeutics to provide corporate communications support.